Business Context and Reporting Period
Seer, Inc. (Nasdaq: SEER), a life sciences company commercializing a proteomics platform, filed this Form 8-K on May 10, 2021, to report financial results for the quarter ended March 31, 2021. The company is advancing the second phase of its commercialization plan, focusing on the Proteograph Product Suite for research use only.
Key Financial Metrics
| Metric | Q1 2021 | Q1 2020 |
|---|---|---|
| Revenue | $62,000 | $177,000 |
| Operating Expenses | $16.6 million | $6.0 million |
| Net Loss | $16.4 million | $5.5 million |
| Cash, Cash Equivalents, and Investments | $531 million | N/A (Balance Sheet shows $432 million total assets) |
| Weighted-Average Shares Outstanding | 59.9 million | 8.9 million |
Liquidity: As of March 31, 2021, the company held $445.8 million in cash and cash equivalents and $85.4 million in investments. Total current liabilities were $7.4 million.
Material Changes Versus Prior Period
- Revenue Decline: Revenue decreased by approximately 65% year-over-year, primarily due to reduced activity associated with a Small Business Innovation Research (SBIR) grant from the NIH.
- Expense Increase: Operating expenses nearly tripled to $16.6 million, driven by higher employee compensation, costs associated with being a publicly traded company, and increased product development expenses.
- Net Loss Expansion: Net loss widened to $16.4 million compared to $5.5 million in the prior year period.
- Share Count: Weighted-average shares outstanding increased significantly from 8.9 million to 59.9 million, reflecting capital raising activities.
Outlook, Commentary, and Risks
Management Commentary: CEO Omid Farokhzad highlighted progress in commercialization, including the signing of multiple Limited Release customer agreements and the completion of installations at the Salk Institute. The company has four active collaboration sites, with the OHSU Knight Cancer Institute and the Broad Institute progressing toward larger-scale follow-on studies.
Operational Updates: The company doubled the size of its Redwood City headquarters and strengthened its leadership team with the addition of a VP of Operations and Quality.
Risks and Contingencies: The filing includes standard forward-looking statement disclaimers regarding the timing and ability to enable unbiased, deep, and rapid proteomics at scale. Actual results may differ materially due to known and unknown risks described in the company's SEC filings.
Investor Verification Checklist
- Verify the sustainability of revenue streams given the decline in NIH grant activity.
- Confirm the timeline and conversion rates for "Limited Release" customers to full commercial contracts.
- Review the burn rate relative to the $531 million cash position to assess runway.
- Monitor the progress of pilot studies at the OHSU Knight Cancer Institute and the Broad Institute.
- Assess the impact of increased public company compliance costs on future operating margins.